Early dexamethasone therapy in preterm infants: a follow-up study

Area of Science:

• Neonatal care
• Pediatric pulmonology
• Pharmacology

Background:

• Chronic lung disease (CLD) is a significant complication in premature infants requiring mechanical ventilation.
• Early postnatal dexamethasone has been investigated to prevent CLD.

Purpose of the Study:

• To evaluate the 2-year corrected age outcomes of infants receiving early (<12 hours) dexamethasone therapy for CLD prevention.
• To assess the impact of early dexamethasone on growth, neurodevelopment, and pulmonary function.

Main Methods:

• A double-blind controlled trial involving 133 infants (birth weight 500-1999g) with severe respiratory distress syndrome requiring mechanical ventilation.
• Dexamethasone treatment group received 0.25 mg/kg every 12 hours for 1 week, followed by a 3-week taper.
• Outcomes assessed at 2-year corrected age included medical history, growth, neurological examinations, MDI/PDI scores, pulmonary function, EEG, and evoked potentials.

Main Results:

• Dexamethasone group showed reduced respiratory-related rehospitalizations but had significantly lower body weight and height in boys.
• Higher incidence of neuromotor dysfunction (41.2% vs 31.4%) and lower psychomotor development index (PDI) scores were observed in the dexamethasone group.
• No significant differences were found in mental development index (MDI), vision impairment, or auditory/visual evoked potentials.

Conclusions:

• While early dexamethasone therapy reduces CLD incidence, its current regimen is not recommended due to adverse neuromotor and growth effects in male infants at 2 years.
• Further studies are required to determine optimal dosage, timing, and duration for safe and effective CLD prevention.
• Modifications to the therapeutic regimen are necessary if early dexamethasone is to be used for CLD prevention.